BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carvalho MV, Gonçalves-de-Albuquerque CF, Silva AR. PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases. Int J Mol Sci 2021;22:E805. [PMID: 33467433 DOI: 10.3390/ijms22020805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramirez-Moral I, Ferreira BL, de Vos AF, van der Poll T. Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia. Respir Res 2021;22:230. [PMID: 34412637 DOI: 10.1186/s12931-021-01823-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 He Y, Zou C, Cai Z. Construction and Comprehensive Analysis of the ceRNA Network to Reveal Key Genes for Benign Tracheal Stenosis. Front Genet 2022;13:891741. [DOI: 10.3389/fgene.2022.891741] [Reference Citation Analysis]
3 Alves HR, Lomba GSB, Gonçalves-de-albuquerque CF, Burth P. Irisin, Exercise, and COVID-19. Front Endocrinol 2022;13:879066. [DOI: 10.3389/fendo.2022.879066] [Reference Citation Analysis]
4 Mike JK, Ferriero DM. Efferocytosis Mediated Modulation of Injury after Neonatal Brain Hypoxia-Ischemia. Cells 2021;10:1025. [PMID: 33925299 DOI: 10.3390/cells10051025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rong P, Wang J, Angelova A, Almsherqi ZA, Deng Y. Plasmalogenic Lipid Analogs as Platelet-Activating Factor Antagonists: A Potential Novel Class of Anti-inflammatory Compounds. Front Cell Dev Biol 2022;10:859421. [DOI: 10.3389/fcell.2022.859421] [Reference Citation Analysis]
6 Tsujiya Y, Hasegawa A, Yamamori M, Okamura N. Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines. Biol Pharm Bull 2022;45:276-83. [PMID: 35228393 DOI: 10.1248/bpb.b21-00785] [Reference Citation Analysis]
7 Fu Y, Ho W, Kang N, Tsai M, Wu J, Huang L, Weng C. Pharmaceutical Prospects of Curcuminoids for the Remedy of COVID-19: Truth or Myth. Front Pharmacol 2022;13:863082. [DOI: 10.3389/fphar.2022.863082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yonekawa A, Shimono N. Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). Biology (Basel) 2022;11:400. [PMID: 35336774 DOI: 10.3390/biology11030400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hsieh MS, Hu SY, Liao SH, Chang CM, Hsieh VC, How CK. Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan. Emerg Med Int 2021;2021:4916777. [PMID: 34394992 DOI: 10.1155/2021/4916777] [Reference Citation Analysis]
10 Izadparast F, Riahi-zajani B, Yarmohammadi F, Hayes AW, Karimi G. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle. [DOI: 10.1080/15384101.2022.2100682] [Reference Citation Analysis]
11 Robinson C, Lockey RF, Kolliputi N. Can PPAR γ Keep Cadmium in Check? Biomolecules 2022;12:1094. [DOI: 10.3390/biom12081094] [Reference Citation Analysis]
12 Wu Q, Jiang Y, You C. The SUMO components in rheumatoid arthritis. Rheumatology (Oxford) 2022:keac297. [PMID: 35595244 DOI: 10.1093/rheumatology/keac297] [Reference Citation Analysis]
13 Zúñiga-Hernández J, Sambra V, Echeverría F, Videla LA, Valenzuela R. N-3 PUFAs and their specialized pro-resolving lipid mediators on airway inflammatory response: beneficial effects in the prevention and treatment of respiratory diseases. Food Funct 2022;13:4260-72. [PMID: 35355027 DOI: 10.1039/d1fo03551g] [Reference Citation Analysis]